BioCentury | Sep 4, 2020
Product Development

Akebia’s prospects dim after safety readout in non-dialysis CKD patients

...did not increase risk of MACE vs. epoetin alfa...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...prior. The exception is Retacrit epoetin alfa-epbx, which is priced below the 2005 level of Epogen epoetin alfa...
...Amgen is on both sides of the biosimilar equation, fighting off competition for Neulasta and Epogen...
BioCentury | Jul 10, 2019
Politics & Policy

CMS’s new CKD payment models could be mixed bag for drug companies

...these patients are erythropoiesis stimulating agents (ESAs). In the U.S., Amgen Inc. (NASDAQ:AMGN) markets Epogen epoetin alfa...
...The ESA now also faces biosimilar competition from Pfizer Inc. (NYSE:PFE), which launched its Retacrit epoetin alfa-epbx...
...for publication to questions on the potential ramifications of the new payment models on its Epogen...
BioCentury | May 11, 2019
Clinical News

FibroGen falls on U.S. safety data for roxadustat

...and myocardial infarction, in pooled Phase III analyses against placebo in non-dialysis-dependent patients and against epoetin alfa...
...is no clinically meaningful difference in risk of MACE between roxadustat" and either placebo or epoetin alfa...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Nov 16, 2018
Clinical News

Pfizer launches U.S.’s first biosimilar epoetin

...Pfizer Inc. (NYSE:PFE) launched the first biosimilar of anemia drug epoetin alfa in the U.S., priced at...
...a 33.5% discount to the lowest priced reference product. Amgen Inc. (NASDAQ:AMGN) markets reference drug Epogen...
...Inc. (NYSE:PFE), New York, N.Y. Product: Retacrit epoetin alfa-epbx Business: Hematology Chris Lieu Retacrit, Silapo, biosimilar epoetin zeta, epoetin alfa Pfizer...
BioCentury | Nov 15, 2018
Company News

Pfizer launches U.S.’s first biosimilar epoetin

...Pfizer Inc. (NYSE:PFE) launched the first biosimilar of anemia drug epoetin alfa in the U.S., priced at...
...a 33.5% discount to the lowest priced reference product. Amgen Inc. (NASDAQ:AMGN) markets reference drug Epogen...
..."FDA approves Pfizer's Retacrit, First Epoetin Alfa Biosimilar in U.S." ). Chris Lieu Retacrit, Silapo, biosimilar epoetin zeta, epoetin alfa Pfizer...
BioCentury | Jul 27, 2018
Regulation

Biosimilar barriers

...status Johnson & Johnson (NYSE:JNJ) Remicade infliximab $4,525.0 8/24/98 2018 Marketed Amgen Inc. (NASDAQ:AMGN) Epogen epoetin alfa...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...Pfizer Inc. (NYSE:PFE) / Stada Arzneimittel AG (Xetra:SAZ) FDA approves Retacrit epoetin alfa-epbx, a biosimilar of Epogen...
BioCentury | May 18, 2018
Clinical News

FDA approves Pfizer's Retacrit, first epoetin alfa biosimilar in U.S.

...FDA approved Retacrit epoetin alfa-epbx from Pfizer Inc. (NYSE:PFE), a biosimilar of anemia drugs Epogen from Amgen...
...cost (WAC) of Epogen and Procrit. The WAC for 2 ml of 10,000 units/ml of Epogen...
...Retacrit epoetin alfa-epbx Business: Hematology Chris Lieu Epogen, epoetin alfa (Epoetin alfa/Epoetin beta, erythropoietin) Eprex, Procrit, epoetin alfa (EPO) Retacrit, Silapo, biosimilar epoetin zeta, epoetin alfa Amgen...
Items per page:
1 - 10 of 804